摘要
目的:分析肝癌患者肠道共生菌及代谢产物分布状态及其与肝癌进展的相关性。方法:选取2017年12月至2018年12月确诊的首发肝癌患者105例,随访收集患者病情进展信息以及死亡情况,检测提示病情的相关恶性生物标志物水平以及肿瘤标志物水平。采集受试者确诊时粪便样本,测定其肠道共生菌分布情况,全部患者随访1年,观察患者病情变化以及生存情况,同时分析肠道共生菌及其代谢产物与患者病情预后的关联情况。结果:随访预后不良者(死亡和病情进展者)相关恶性指标水平更高。患者优势共生菌前两位为嗜乳酸菌和双歧杆菌,随访死亡组嗜乳酸菌、双歧杆菌及其代谢产物吲哚的水平更低,差异有统计学意义(P<0.01)。以病情进展为因变量,以共生菌、共生菌代谢产物及其他潜在影响因素为自变量,使用回归模型讨论肠道共生菌及其代谢产物与肝癌进展的关联,结果提示嗜乳酸菌和双歧杆菌两种肠道共生菌每克粪便细菌拷贝数增高以及它们共有的代谢产物吲哚表达增高,均为肝癌进展的保护因素。以肝癌常见的恶性生化指标以及分子标志物(AFP-L3、VEGF、aFGF和bFGF)为因变量,以共生菌、共生菌代谢产物及其他潜在影响因素为自变量,使用回归模型讨论肠道共生菌及其代谢产物与这些指标之间的关联,结果提示嗜乳酸菌和双歧杆菌两种肠道共生菌每克粪便细菌拷贝数增高以及它们共有的代谢产物吲哚表达增高,均与肝癌进展相关指标水平增高呈负相关,它们也可能是肝癌进展的保护因素。结论:肝癌患者肠道共生菌及代谢产物具有一定的减缓肝癌进展的辅助作用,值得临床关注。
Objective:To analyze the distribution status of intestinal commensal bacteria and metabolites in patients with liver cancer and their correlation with liver cancer progression.Methods:The study selected 105 patients with the first diagnosis of liver cancer from December 2017 to December 2018 in our hospital.Stool samples were taken from the subjects at the time of diagnosis to determine the distribution of intestinal commensal bacteria.All patients were followed up for 1 year to observe the patient's condition changes and survival status for 1 year.At the same time,the association of intestinal commensal bacteria and their metabolites with the patient's prognosis was analyzed.To analyze the distribution status of intestinal commensal bacteria and metabolites in patients with liver cancer and their correlation with liver cancer progression,statistical analysis was performed using SPSS statistical software package.Results:In this study,we can see that patients include patients with stage Ⅰ,Ⅱ,and Ⅲ liver cancer.The distribution of basic characteristics such as gender and age of patients in different stages is fully comparable.Follow-up collection of patients'disease progression information and death.The prognosis of patients with high stage is relatively poor.Meet the basic characteristics of the disease.The study also collected the levels of malignant biomarkers and tumor markers that suggest the condition,and it can be seen that those with poor prognosis during follow-up(death and disease progression)have higher levels of related indicators.The top two symbiotic bacteria among the patients were Lactobacillus and Bifidobacterium.The study focused on the intestinal symbiotic bacteria and the metabolite indole shared by the two symbiotic bacteria.Lactobacillus and bifidobacteria were both lower,and the level of metabolite indole was also seen to be lower,the difference was statistically significant.Taking disease progression as the dependent variable and symbiotic bacteria,symbiotic bacteria metabolites and oth
作者
李洪波
匡黎
LI Hong-bo;KUANG Li(Department of Oncology,Sinopharm Dongfeng General Hospital Affiliated to Hubei Medical College,Shiyan Hubei,100053,China)
出处
《中西医结合肝病杂志》
CAS
2021年第10期897-900,共4页
Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases
关键词
原发性肝癌
肠道共生菌
吲哚
相关性
primary liver cancer
intestinal symbiotic bacteria
intestinal symbiotic bacteria metabolites
correlation
